0001511164-16-001107.txt : 20161107 0001511164-16-001107.hdr.sgml : 20161107 20161107144256 ACCESSION NUMBER: 0001511164-16-001107 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20161107 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20161107 DATE AS OF CHANGE: 20161107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-201719 FILM NUMBER: 161977690 BUSINESS ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 BUSINESS PHONE: (416) 214-3678 MAIL ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 8-K 1 form8kbiotricity11716.htm FORM 8-K Converted by EDGARwiz





UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K


CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 7, 2016



BIOTRICITY INC.

(Exact Name of Registrant as Specified in Its Charter)



Nevada

 

333-201719

 

47-2548273

(State or Other Jurisdiction of Incorporation or Organization)

 

(Commission File Number)

 

(IRS Employer Identification No.)


75 International Blvd., Suite 300

Toronto, ON

 


M9W 6L9

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (416) 214-3678

 

 

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))









Item 8.01

Other Events

On November 7, 2016, Biotricity, Inc., a Nevada corporation (the “Registrant”), released a letter to shareholders to provide an update on the Registrant’s progress.

A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits.  The exhibit listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K:

Exhibit No.


Description

 

 

99.1

Letter to Shareholders




2





SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  November 7, 2016

 

 

BIOTRICITY INC.

 

 

 

 

By:

/s/ Waqaas Al-Siddiq

 

 

Waqaas Al-Siddiq

 

 

Chief Executive Officer

 





3



 EX-99.1 2 lettertoshareholdersbiotrici.htm LETTER TO SHAREHOLDERS Converted by EDGARwiz



Dear Shareholders,

It has been a while since my last communication, so I wanted to provide an update on our progress. By most accounts, we have progressed rapidly and are executing our plans successfully. On the business side of things:

1.

We have begun building out our Business Development and Sales team with individuals who have vast experience in the MCT and cardiac monitoring market. We have made significant progress on the telecom side with AT&T becoming our preferred partner for telecom services for our solution. We are also building out additional strategic partnerships.

2.

We have a strong advisory board and board of directors that we will continue to build out over the next year.

3.

Our product has gotten great feedback from the small sample size of Cardiologists and Electrophysiologists that we have spoken to and we believe we will do very well once we enter the market. We have received great press and media coverage. The company has been featured twice in Forbes, in CB Insights, and in other major outlets. We aim to be a major thought leader in our industry.

On the regulatory side we are moving along well:

1.

We created our own variation of the ECG software and have received clearance on that. The clearance was received on October 13 for a Class II medical product, which speaks to the strong team we have here.

2.

We are in the middle of preparing our FDA filing for the hardware and expect to get this filed by the end of 2016.

Regarding corporate matters, we have been working on capital, developing an audience for the company, and getting our S-1 filing complete. Some details:

1.

We did a bridge capital round over the summer because summers are typically very slow. This was successful and oversubscribed.

2.

We are working on establishing a larger audience for our news. If you know anyone that is interested in healthcare related news, please let us know and we will happily add them to our mailing list. Alternatively, you can contact us at social@biotricity.com

3.

With regards to our former iMedical shareholders, we are working hard on getting the S-1 effective with the SEC. Although this can be an arduous process and we cannot control how long it will take, we have made it a priority.

As always, please contact us if you have any questions.

Thank you for your continued support,

Waqaas

Chairman and CEO